The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Estimated Market Size Of The Biosimilar Monoclonal Antibodies Market In 2026, And How Will Its Value Evolve By 2030?
The biosimilar monoclonal antibodies market size has shown significant expansion in recent years. It is anticipated to expand from $10.64 billion in 2025 to $11.29 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.2%. The past growth can be ascribed to several factors, including the high cost of originator biologics, the increasing burden of chronic and autoimmune diseases, the expiration of patents for blockbuster monoclonal antibodies, rising healthcare expenditure, and a gradual improvement in regulatory clarity for biosimilars.
The biosimilar monoclonal antibodies market is anticipated to experience substantial expansion in the coming years. This market is projected to reach $14.58 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.6%. The drivers for this growth during the forecast period include the expanding pipelines of biosimilars, a rising demand for cost-effective biologic treatments, an increase in approvals in emerging markets, advancements in biopharmaceutical manufacturing, and supportive government policies encouraging biosimilar adoption. Major trends expected in the forecast period encompass the increasing uptake of economical biosimilar monoclonal antibodies, a broader application of biosimilars in oncology and autoimmune disorders, growing acceptance from both physicians and patients, the expansion of regulatory approvals across global markets, and an elevated focus on improving access to biologic therapies.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3412&type=smp
What Major Factors Are Driving The Biosimilar Monoclonal Antibodies Market Forward?
An anticipated increase in autoimmune diseases is set to boost the expansion of the biosimilar monoclonal antibodies market in the future. These conditions involve the immune system erroneously attacking the body’s own tissues and organs. The escalation of autoimmune diseases is largely attributable to greater exposure to environmental factors like pollution and chemicals, which can disturb immune equilibrium and encourage irregular immune reactions. Biosimilar monoclonal antibodies offer a solution to the growing prevalence of autoimmune diseases by supplying cost-effective, efficacious, and readily available targeted treatments that regulate excessive immune responses in patients. For example, data from February 2024, provided by Arthritis Australia, an Australia-based non-profit organization, indicates that in 2025, an estimated 212,136 males and 362,137 females are projected to have rheumatoid arthritis (RA). These figures are anticipated to climb by 2040 to approximately 280,040 males and 479,828 females. Consequently, the increasing occurrence of autoimmune diseases is propelling the expansion of the biosimilar monoclonal antibodies market.
What Are The Different Segment Types In The Biosimilar Monoclonal Antibodies Market Segment Breakdown?
The biosimilar monoclonal antibodies market covered in this report is segmented –
1) By Type: Biopharmaceuticals, Other Types
2) By Compound: Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab
3) By Application: Chronic & Autoimmune Diseases, Oncology, Other Applications
Subsegments:
1) By Biopharmaceuticals: Monoclonal Antibodies, Recombinant Proteins, Vaccines, Other Biopharmaceuticals
2) By Other Types: Antibody-Drug Conjugates, Fusion Proteins, Biosimilars Of Other Biologics
What Trends Are Affecting The Growth Of The Biosimilar Monoclonal Antibodies Market?
Leading companies in the biosimilar monoclonal antibody market are developing biosimilar versions of monoclonal antibodies to provide cost-effective alternatives to original therapies, thus improving access and affordability in healthcare. An intravenous formulation refers to an antibody preparation designed for direct administration into the bloodstream through a vein for rapid therapeutic effect. For instance, in May 2024, Bio-Thera Solutions, a China-based biopharmaceutical company, and Biogen Inc., a US-based biopharmaceutical company, launched TOFIDENCE (tocilizumab-bavi) in an intravenous formulation in the United States. The U.S. Food and Drug Administration had approved TOFIDENCE in September 2023 for treating moderately to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis. At its launch, TOFIDENCE is available in three vial sizes: 80 mg/4 mL, 200 mg/10 mL, and 400 mg/20 mL for intravenous infusion, with subcutaneous formulations scheduled for future release.
Who Are The Well-Known Companies In The Biosimilar Monoclonal Antibodies Market?
Major companies operating in the biosimilar monoclonal antibodies market are Pfizer Inc., Novartis AG, AbbVie Inc., Coherus BioSciences, Biocon Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Celltrion Inc., BioXpress Therapeutics SA, Intas Pharmaceuticals Limited, Genor BioPharma Co. Ltd., BIOCAD, Dr. Reddy’s Laboratories Ltd., 3SBio Inc., Reliance Life Sciences, Hisun Pharmaceuticals, Celgen Biopharmaceuticals, Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd., Shanghai Henlius Biotech Inc., Teva Pharmaceutical Industries Ltd., Alvotech, Xentria Inc., Lazuline Biotech Private Limited, Epygen Biotech Pvt Ltd., Mabpharm Limited, Qilu Pharmaceutical Co. Ltd., Chiatai Tianqing Pharmaceutical Group Co. Ltd., YL Biologics Ltd., Aprogen Biologics, UNDBIO Co Ltd., Samsung Bioepis Co. Ltd., ISU Abxis Corp., Bio-Rad Laboratories Inc.
Get The Full Biosimilar Monoclonal Antibodies Market Report:
Which Region Is The Largest In The Biosimilar Monoclonal Antibodies Market?
North America was the largest region in the biosimilar monoclonal antibodies market in 2025. The regions covered in the biosimilar monoclonal antibodies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Biosimilar Monoclonal Antibodies Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Biosimilar Monoclonal Antibodies Market 2026, By The Business Research Company
Biologics Market 2026
https://www.thebusinessresearchcompany.com/report/biologics-market
Pharmaceutical Drugs And Biologics Logistics Market 2026
Anti Asthmatics And Copd Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model